Cargando…

Growth Hormone Treatment in Turner's Syndrome: A Real World Experience

OBJECTIVE: Short stature is a universal clinical feature of Turner's syndrome (TS). Growth failure begins in fetal life, and adults with TS are on an average 20 cm shorter than the normal female population. Since there is a paucity of data from India regarding the effect of growth hormone (GH)...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy Danda, Vijay Sheker, Sreedevi, P., Arun, G., Rao, P. Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434718/
https://www.ncbi.nlm.nih.gov/pubmed/28553590
http://dx.doi.org/10.4103/ijem.IJEM_36_17
_version_ 1783237102230568960
author Reddy Danda, Vijay Sheker
Sreedevi, P.
Arun, G.
Rao, P. Srinivas
author_facet Reddy Danda, Vijay Sheker
Sreedevi, P.
Arun, G.
Rao, P. Srinivas
author_sort Reddy Danda, Vijay Sheker
collection PubMed
description OBJECTIVE: Short stature is a universal clinical feature of Turner's syndrome (TS). Growth failure begins in fetal life, and adults with TS are on an average 20 cm shorter than the normal female population. Since there is a paucity of data from India regarding the effect of growth hormone (GH) on TS patients, we retrospectively analyzed the data of TS patients who are on GH treatment. METHODS: This hospital-based observational retrospective study was conducted in a tertiary care hospital of Hyderabad. The data such as height, weight, and bone age of 16 patients who are diagnosed with TS on GH therapy for at least 6 months were included in the study. All the patients were treated with human recombinant GH at the dose of 0.3 mg/kg/week administered as daily subcutaneous injections. RESULTS: The mean age at diagnosis was 12.7 years. The mean height at the start of GH therapy was 1.26 m, and mean height standard deviation score (HSDS) was-0.61 when compared to Turner's specific reference data. With a mean duration of GH therapy of 25 months, the mean height at the end of therapy was 1.37 m and the mean height as per HSDS was + 0.37 resulting in a mean height gain of + 0.99 HSDS. CONCLUSION: Our observation shows that girls with TS benefit from early diagnosis and initiation of treatment with GH.
format Online
Article
Text
id pubmed-5434718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-54347182017-05-26 Growth Hormone Treatment in Turner's Syndrome: A Real World Experience Reddy Danda, Vijay Sheker Sreedevi, P. Arun, G. Rao, P. Srinivas Indian J Endocrinol Metab Original Article OBJECTIVE: Short stature is a universal clinical feature of Turner's syndrome (TS). Growth failure begins in fetal life, and adults with TS are on an average 20 cm shorter than the normal female population. Since there is a paucity of data from India regarding the effect of growth hormone (GH) on TS patients, we retrospectively analyzed the data of TS patients who are on GH treatment. METHODS: This hospital-based observational retrospective study was conducted in a tertiary care hospital of Hyderabad. The data such as height, weight, and bone age of 16 patients who are diagnosed with TS on GH therapy for at least 6 months were included in the study. All the patients were treated with human recombinant GH at the dose of 0.3 mg/kg/week administered as daily subcutaneous injections. RESULTS: The mean age at diagnosis was 12.7 years. The mean height at the start of GH therapy was 1.26 m, and mean height standard deviation score (HSDS) was-0.61 when compared to Turner's specific reference data. With a mean duration of GH therapy of 25 months, the mean height at the end of therapy was 1.37 m and the mean height as per HSDS was + 0.37 resulting in a mean height gain of + 0.99 HSDS. CONCLUSION: Our observation shows that girls with TS benefit from early diagnosis and initiation of treatment with GH. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5434718/ /pubmed/28553590 http://dx.doi.org/10.4103/ijem.IJEM_36_17 Text en Copyright: © 2017 Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Reddy Danda, Vijay Sheker
Sreedevi, P.
Arun, G.
Rao, P. Srinivas
Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title_full Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title_fullStr Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title_full_unstemmed Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title_short Growth Hormone Treatment in Turner's Syndrome: A Real World Experience
title_sort growth hormone treatment in turner's syndrome: a real world experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434718/
https://www.ncbi.nlm.nih.gov/pubmed/28553590
http://dx.doi.org/10.4103/ijem.IJEM_36_17
work_keys_str_mv AT reddydandavijaysheker growthhormonetreatmentinturnerssyndromearealworldexperience
AT sreedevip growthhormonetreatmentinturnerssyndromearealworldexperience
AT arung growthhormonetreatmentinturnerssyndromearealworldexperience
AT raopsrinivas growthhormonetreatmentinturnerssyndromearealworldexperience